Gilead Sciences, a prominent global biopharmaceutical company, has revealed the signing of a Memorandum of Understanding (MoU) with the Saudi Oncology Society (SOS) to collaborate in research, clinical trials, medical education, and scientific exchange. Committed to promoting a healthier world through the exchange of scientific and innovative advancements, Gilead Sciences will closely work with SOS to achieve these objectives.
The main focus of their joint effort is on education, research, awareness, optimizing treatment management, and guiding the audience to specialized healthcare professionals. These contributions aim to expand and enhance the broader healthcare system in the Kingdom, with a particular emphasis on oncology and addressing the unmet needs of cancer patients in the region.
As per the MoU, the agreement is initially set for three years with the possibility of extension, demonstrating Gilead and SOS's shared commitment to making meaningful contributions to the field of oncology.
Vitor Papao, General Manager of Gilead Sciences Middle East, emphasized the company's mission to collaborate with leading oncologists and institutions in the region, aiming to advance clinical development, promote healthcare equity, and support healthcare professionals while improving patient outcomes. Gilead's substantial investment in the region underscores its dedication to working closely with local partners to ensure patients promptly receive their groundbreaking therapies.
Dr. Meteb Al-Foheidi, Chairperson of the Saudi Oncology Society, expressed pride in embarking on a transformative journey with Gilead Sciences. He highlighted their ongoing efforts to advance cancer research, clinical trials, and medical education in the Kingdom. The three-year agreement signals their anticipation of making meaningful contributions to the field of oncology and enhancing the broader healthcare landscape in Saudi Arabia.
The partnership involves regular meetings between Gilead Sciences and SOS to align and implement initiatives, ensuring a continued focus on their shared objectives. The collaboration aims to support healthcare professionals, enhance patient outcomes, and contribute to the broader healthcare ecosystem in Saudi Arabia. It places emphasis on education, research, awareness, and optimizing treatment.
